Federal Register / Vol. 60, No. 48 / Monday, March 13, 1995 / Notices 13437

Secretary, Board of Governors of the

Federal Reserve System, Washington,

D.C. 20551, not later than March 29,

1995. Any request for a hearing on this

application must, as required by §

262.3(e) of the Board’s Rules of

Procedure (12 CFR 262.3(e)), be

accompanied by a statement of the

reasons why a written presentation

would not suffice in lieu of a hearing,

identifying specifically any questions of

fact that are in dispute, summarizing the

evidence that would be presented at a

hearing, and indicating how the party

commenting would be aggrieved by

approval of the proposal.

This application may be inspected at

the offices of the Board of Governors or

the Federal Reserve Bank of Cleveland.

Board of Governors of the Federal Reserve

System, March 7, 1995.

Jennifer J. Johnson,

Deputy Secretary of the Board.

[FR Doc. 95–6073 Filed 3–10–95; 8:45 am]

BILLING CODE 6210–01–F

GENERAL SERVICES

ADMINISTRATION

Change in Solicitation Procedures

Under the Small Business

Competitiveness Demonstration

Program

AGENCY: Office of Acquisition Policy,

GSA.

ACTION: Notice.

SUMMARY: Title VII of the ‘‘Business

Opportunity Development Act of 1988’’

(Public Law 100–656) established the

Small Business Competitiveness

Demonstration Program and designated

nine (9) agencies, including GSA, to

conduct the program over a four (4) year

period from January 1, 1989 to

December 31, 1992. The Small Business

Opportunity Enhancement Act of 1992

(Public Law 102–366) extended the

demonstration program until September

1996 and made certain changes in the

procedures for operation of the

demonstration program. The law

designated four (4) industry groups for

testing whether the competitive

capabilities of the specified industry

groups will enable them to successfully

compete on an unrestricted basis. The

four (4) industry groups are:

construction (except dredging);

architectural and engineering (A&E)

services (including surveying and

mapping); refuse systems and related

services (limited to trash/garbage

collection); and non-nuclear ship repair.

Under the program, when a

participating agency misses its small

business participation goal, restricted

competition is reinstituted only for

those contracting activities that failed to

attain the goal. The small business goal

is 40 percent of the total contract dollars

awarded for construction, trash/garbage

collection services, and non-nuclear

ship repair and 35 percent of the total

contract dollars warded for architectengineer services. This notice

announces modifications to GSA’s

solicitation practices under the

demonstration program based on a

review of the agency’s performance

during the period from January 1, 1994

to December 31, 1994. Modifications to

solicitation practices are outlined in the

Supplementary Information section

below and apply to solicitations issued

on or after April 1, 1995.

EFFECTIVE DATE: April 1, 1995.

FOR FURTHER INFORMATION CONTACT:

Tom Wisnowski, Office of GSA

Acquisition Policy, (202) 501–1224.

SUPPLEMENTARY INFORMATION:

Procurements of construction or trash/

garbage collection with an estimated

value of $25,000 or less will be reserved

for emerging small business concerns in

accordance with the procedures

outlined in the interim policy directive

issued by the Office of Federal

Procurement Policy (58 FR 13513,

March 11, 1993).

Procurements of construction or

trash/garbage collection with an

estimated value that exceeds $25,000 by

GSA contracting activities will be made

in accordance with the following

procedures:

Construction Services in Groups 15, 16,

and 17

Procurements for all construction

services (except solicitations issued by

GSA contracting activities in Regions 1,

2, 5, 6, 7, 9 and the National Capital

Region in SIC Group 15, Regions 2, 5

and 9 for individual SIC code 1794, and

Regions 1, 3, 4, 5, 7, 9 and the National

Capital Region for individual SIC code

1796) shall be conducted on an

unrestricted basis.

Procurements for construction

services in SIC Group 15 issued by GSA

contracting activities in Regions 1, 2, 5,

6, 7, 9, and the National Capital Region,

for individual SIC code 1794 in Regions

2, 5 and 9, and for individual SIC Code

1796 in Regions 1, 3, 4, 5, 7, 9, and the

National Capital Region, shall be set

aside for small business when there is

a reasonable expectation of obtaining

competition for two or more small

businesses. If no expectation exists, the

procurements will be conducted on an

unrestricted basis.

Region 1 encompasses the states of

Connecticut, Maine, Massachusetts,

New Hampshire, Rhode Island and

Vermont.

Region 2 encompasses the states of

New Jersey, New York, and the

territories of Puerto Rico and the Virgin

Islands.

Region 3 encompasses the states of

Pennsylvania, Delaware, West Virginia,

Maryland (except Montgomery and

Prince Georges counties), and Virginia

(except the city of Alexandria and the

counties of Arlington, Fairfax, Loudoun,

and Prince William).

Region 4 encompasses the states of

Alabama, Florida, Georgia, Kentucky,

North Carolina, South Carolina,

Mississippi, and Tennessee.

Region 5 encompasses the states of

Illinois, Indiana, Ohio, Michigan,

Minnesota, and Wisconsin.

Region 6 encompasses the states of

Iowa, Kansas, Missouri and Nebraska.

Region 7 encompasses the states of

Arkansas, Louisiana, Oklahoma, New

Mexico, and Texas.

Region 9 encompasses the states of

Arizona, California, Hawaii, and

Nevada.

Region 10 encompasses the states of

Alaska, Idaho, Oregon, and Washington.

The National Capital Region

encompasses the District of Columbia,

Montgomery and Prince Georges

counties in Maryland, and the city of

Alexandria and the counties of

Arlington, Fairfax, Loudoun, and Prince

William In Virginia.

Trash/Garbage Collection Services in

PSC S205

Procurements for trash/garbage

collection services in PSC S205 will be

conducted on an unrestricted basis.

Architect-Engineer Services (all PSC

Codes under the Demonstration

Program):

Procurements for all architectengineer services (except procurements

issued by contracting activities in GSA

Region 4 for service code C119, and in

Region 9 for service code C219) shall be

conducted on an unrestricted basis.

Procurements for architect-engineer

services issued by GSA contracting

activities in Region 4 for service code

C119 and in Region 9 for service code

C219 shall be set aside for small

business when there is a reasonable

expectation of obtaining competition

from two or more small businesses. If no

expectation exists, the procurement will

be conducted on an unrestricted basis.

Region 4 encompasses the states of

Alabama, Florida, Georgia, Kentucky,

North Carolina, South Carolina,

Mississippi, and Tennessee.

Region 9 encompasses the states of

Arizona, California, Hawaii, and

Nevada.
13438 Federal Register / Vol. 60, No. 48 / Monday, March 13, 1995 / Notices

Non-Nuclear Ship Repair

GSA does not procure non-nuclear

ship repairs.

Dated: March 2, 1995.

Ida M. Ustad,

Associate Administrator for Acquisition

Policy.

[FR Doc. 95–6113 Filed 3–10–95; 8:45 am]

BILLING CODE 6820–61–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Food and Drug Administration

[Docket No. 95N–0059]

Drug Export; Abbott HTLV–I/HTLV–II

EIA

AGENCY: Food and Drug Administration,

HHS.

ACTION: Notice.

SUMMARY: The Food and Drug

Administration (FDA) is announcing

that Abbott Laboratories, Inc., has filed

an application requesting approval for

the export of the human biological

product HTLV–I/HTLV–II EIA to

Australia, Austria, Belgium, Denmark,

Federal Republic of Germany, Finland,

France, Iceland, Ireland, Italy,

Luxembourg, The Netherlands, New

Zealand, Norway, Portugal, Sweden,

Switzerland, and The United Kingdom.

ADDRESSES: Relevant information on

this application may be directed to the

Dockets Management Branch (HFA–

305), Food and Drug Administration,

rm. 1–23, 12420 Parklawn Dr.,

Rockville, MD 20857, and to the contact

person identified below. Any future

inquiries concerning the export of

human biological products under the

Drug Export Amendments Act of 1986

should also be directed to the contact

person.

FOR FURTHER INFORMATION CONTACT:

Frederick W. Blumenschein, Center for

Biologics Evaluation and Research

(HFM–660), Food and Drug

Administration, 1401 Rockville Pike,

Rockville, MD 20852–1448, 301–594–

1070.

SUPPLEMENTARY INFORMATION: The drug

export provisions in section 802 of the

Federal Food, Drug, and Cosmetic Act

(the act) (21 U.S.C. 382) provide that

FDA may approve applications for the

export of human biological products

that are not currently approved in the

United States. Section 802(b)(3)(B) of

the act sets forth the requirements that

must be met in an application for

approval. Section 802(b)(3)(C) of the act

requires that the agency review the

application within 30 days of its filing

to determine whether the requirements

of section 802(b)(3)(B) have been

satisfied. Section 802(b)(3)(A) of the act

requires that the agency publish a notice

in the Federal Register within 10 days

of the filing of an application for export

to facilitate public participation in its

review of the application. To meet this

requirement, the agency is providing

notice that Abbott Laboratories, Inc.,

One Abbott Park Rd., Abbott Park, IL

60064, has filed an application

requesting approval for the export of the

human biological product Abbott

HTLV–I/HTLV–II EIA to Australia,

Austria, Belgium, Denmark, Federal

Republic of Germany, Finland, France,

Iceland, Ireland, Italy, Luxembourg, The

Netherlands, New Zealand, Norway,

Portugal, Sweden, Switzerland, and The

United Kingdom. The test is intended as

a screen for donated blood to prevent

transmission of HTLV–I and HTLV–II to

recipients of cellular blood products

and as an aid in the clinical diagnosis

of HTLV–I and HTLV–II related

diseases. The application was received

and filed in the Center for Biologics

Evaluation and Research on January 9,

1995, which shall be considered the

filing date for purposes of the act.

Interested persons may submit

relevant information on the application

to the Dockets Management Branch

(address above) in two copies (except

that individuals may submit single

copies) and identified with the docket

number found in brackets in the

heading of this document. These

submissions may be seen in the Dockets

Management Branch between 9 a.m. and

4 p.m., Monday through Friday.

The agency encourages any person

who submits relevant information on

the application to do so by March 23,

1995, and to provide an additional copy

of the submission directly to the contact

person identified above, to facilitate

consideration of the information during

the 30-day review period.

This notice is issued under the

Federal Food, Drug, and Cosmetic Act

(sec. 802 (21 U.S.C. 382)) and under

authority delegated to the Commissioner

of Food and Drugs (21 CFR 5.10) and

redelegated to the Center for Biologics

Evaluation and Research (21 CFR 5.44).

Dated: February 28, 1995.

James C. Simmons,

Acting Director, Office of Compliance, Center

for Biologics Evaluation and Research.

[FR Doc. 95–6127 Filed 3–10–95; 8:45 am]

BILLING CODE 4160–01–F

Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration,

HHS.

ACTION: Notice.

SUMMARY: This notice announces a

forthcoming meeting of a public

advisory committee of the Food and

Drug Administration (FDA). This notice

also summarizes the procedures for the

meeting and methods by which

interested persons may participate in

open public hearings before FDA’s

advisory committees.

FDA has established an Advisory

Committee Information Hotline (the

hotline) using a voice-mail telephone

system. The hotline provides the public

with access to the most current

information on FDA advisory committee

meetings. The advisory committee

hotline, which will disseminate current

information and information updates,

can be accessed by dialing 1–800–741–

8138 or 301–443–0572. Each advisory

committee is assigned a 5-digit number.

This 5-digit number will appear in each

individual notice of meeting. The

hotline will enable the public to obtain

information about a particular advisory

committee by using the committee’s 5-

digit number. Information in the hotline

is preliminary and may change before a

meeting is actually held. The hotline

will be updated when such changes are

made.

MEETING: The following advisory

committee meeting is announced:

Blood Products Advisory Committee

Date, time, and place. March 15,

1995, 1:30 p.m., Food and Drug

Administration, Nicholson Lane

Research Center, conference room 244B,

5516–B Nicholson Lane, Kensington,

MD.

Type of meeting and contact person.

This meeting will be held by a

telephone conference call. A speaker

telephone will be provided in the

conference room to allow public

participation in the meeting. Open

committee discussion, March 15, 1995,

1:30 p.m. to 2:35 p.m.; closed committee

deliberations, 2:35 p.m. to 3:35 p.m.;

open public hearing, 3:35 p.m. to 4:35

p.m., unless public participation does

not last that long; Linda A. Smallwood,

Center for Biologics Evaluation and

Research (HFM–350), Food and Drug

Administration, 1401 Rockville Pike,

Rockville, MD 20852, 301–594–6700, or

FDA Advisory Committee Information

Hotline, 1–800–741–8138 (301–443–

0572 in the Washington, DC area), Blood

Products Advisory Committee, code

12388.